Temasek-Backed Tessa Therapeutics to Liquidate
Posted on 07/01/2023
Singapore-based Tessa Therapeutics Ltd. was backed by major local investors including Temasek Holdings and EDBI. The pharma company is set to liquidate after they were not able to attract more capital or find a strategic buyer. The company is involved in the development of its cancer treatment cell therapies. Tessa is working on autologous cell therapies in nasopharyngeal cancer and classical Hodgkin lymphoma.
In June 2022, Tessa Therapeutics announced the close of a US$ 126 million Series A financing round. Polaris Partners led the financing with participation from existing investors, including Temasek, EDBI, Heliconia Capital, and Heritas Capital.